Nobilis Therapeutics said yesterday that it filed an investigational new drug application with the FDA to kick off a Phase IIb trial of its NBTX-001 drug-device PTSD therapy.
The Portland, Ore.-based company is developing a portable inhalation device designed to deliver a xenon gas mixture.
Nobilis plans to conduct a 200-patient clinical trial with both combat-related and non-military forms of PTSD. The study will include five weeks of treatment and a seven-week follow-up period.
If the study is successful, Nobilis said it will conduct a pivotal trial.
“This IND filing is an important step forward for the company as it looks to position NBTX-001 as a dramatic departure from conventional treatments for psychiatric diseases. PTSD is a devastating disease associated with tremendous emotional and financial costs to the health care system that is devoid of effective treatment options,” founder & CEO Dr. Vlad Bogin said in prepared remarks.
“As we enter the clinical stage of development, our focus is to continue to advance NBTX-001 rapidly through its planned clinical program together with the clinical team at McLean Hospital, psychiatric affiliate of Harvard Medical School,” Bogin added.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.